After the success of the 10th anniversary of the World Stem Cells & Regenerative Medicine Congress in 2015, it is time once again for the stem cells and regenerative medicine industries to come together and this time look forward to the next 10 years of commercial successes within these two sectors.
The Congress has traditionally focused on developing the commercial aspects of stem cells, with the addition of innovation within regenerative medicine, notably tissue engineering. Now the first cell therapies have made it to market, it is important, for the success of the sector, to move forward and include new projects and innovations that are coming out of academia and university spin-outs. These will be both new developments in cell therapy but also within the use of stem cells for drug discovery.
Alongside the stem cells content, there is an increasing amount of demand for other forms of regenerative medicine and so the Congress will move to include more commercial opportunities within the field of tissue engineering: markedly biological scaffolds, 3D bioprinting and organ regeneration.
Through the last 10 years the Congress has built up a reputation for delivering high-level commercial content and bringing together the senior executives and thought-leaders within the space. As the Congress moves to look forward to the next 10 years, the event will move to incorporate insights and attendance from across the value chain: from innovation through to application. As we reach our 11th anniversary, we asked some of the speakers to give us their thoughts on the biggest achievements over the past 12 months as well as their expectations for the year ahead. This e-book contains just a handful of those answers to give you a taste of what to expect in May.
- Andre Choulika, Chairman & Chief Executive Officer, Cellectis
- Claudia Mitchell, Chief Executive Officer, Universal Cells
- David Sourdive, Executive Vice President, Corporate Development, Cellectis
- Fred Miesowicz, COO, Argos Therapeutics
- Hardy T S Kagimoto, President & CEO, Healios
- Kristin Comella, Chief Scientific Officer, US Stem Cell, Inc
- Mark Curtis, Associate, CCRM
- Oren Levy, Instructor in Medicine, Brigham and Women’s Hospital
- Philip Newsome, Head of Cell Therapy, University of Birmingham
- Toshio Miyata, Executive director, Health and Global Policy Institute (HGPI)
For more information on the Stem Cells & Regenerative Medicine Congress 2o16 taking place this 18-20th May at the Business Design Centre, download the brochure.